| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320800 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7393543 | FERRING | Vaginally administratable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
| US7300664 | FERRING | Vaginally administrable progesterone-containing tablets and method for preparing same |
Nov, 2019
(4 years ago) | |
Endometrin is owned by Ferring.
Endometrin contains Progesterone.
Endometrin has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Endometrin are:
- US7320800
- US7393543
- US7300664
Endometrin was authorised for market use on 21 June, 2007.
Endometrin is available in insert;vaginal dosage forms.
Endometrin can be used as support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women, endometrin is a progesterone indicated to support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women.
The generics of Endometrin are possible to be released after 17 November, 2019.
Drugs and Companies using PROGESTERONE ingredient
Market Authorisation Date: 21 June, 2007
Treatment: Support embryo implantation and early pregnancy by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women; Endometrin is a...
Dosage: INSERT;VAGINAL
ENDOMETRIN family patents
